Samsung Biologics (KRX:207940) is planning to separate its biosimilar and its contract development and manufacturing Organization (CDMO) business via a spin-off, according to a Thursday release.
The spin-off will result in the establishment of a new holding company, Samsung Epi Holdings, which will take full ownership of Samsung Bioepis. Samsung Bioepis CEO Kim Kyung-ah will head the new entity, the release said.
Meanwhile, Samsung Biologics will remain focused solely on its CDMO business.
The split will be finalized after shareholder approval on Sept. 16, with Samsung Epi Holdings' official launch set for Oct. 1. Both companies are scheduled to be listed separately on Oct. 29, it said.
Shares of Samsung Biologics fell nearly 2% at market close on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.